Americans expect and deserve consistent healthcare product labeling, no matter what state they buy or use the items in. It is in every citizen's best interest for the federal government to retain authority over safety labeling standards. Centralized regulation removes variability and guarantees the reliability of health data listed on consumer product packaging from coast to coast.
FDA issued a proposed rule on labeling requirements for OTC human drugs. The announcement proposed a definition for “convenience-size” OTC drug packages as well as the option of alternative labeling requirements for these products. CHPA welcomes the opportunity to comment on the proposed rule changes.
CHPA appreciates the opportunity to provide comments concerning U.S. Government positions in preparation for the 33rd session of the Codex Committee on Food Labelling of the Codex Alimentarius Commission.
CHPA welcomes the opportunity to provide comments to this proposed rule on nutrient content and health claims and supports the Agency’s efforts to facilitate the communication of truthful and non-misleading information to consumers.
CHPA welcomes the opportunity to be a participant in this rulemaking process for health claims and dietary guidance and supports the Agency’s efforts to develop a process that facilitates the communication of information to consumers about health claims on food and dietary supplement products.
On behalf of member companies who manufacture and distribute dietary supplement products, CHPA requests an extension of the comment period on the Advance Notice of Proposed Rulemaking for Food Labeling for Health Claims and Dietary Guidance.
CHPA supports the intent of the proposed rule to add a bar code to many medications intended to be dispensed in hospitals. We support the view that this rule will help arm busy healthcare professionals with technology to help avoid medication mistakes.
CHPA supports efforts to reduce medication errors, including those that encompass errors in information acquisition by the consumer, who is the principal end user of self care products, and by health professionals as well.
Request for agency exercise of enforcement discretion regarding the addition of new Warning language to Drug Facts labeling for Over-the-Counter benzocaine liquid/gel products indicated for relieving oral discomfort.
FDA Announcement of a proposed safety-based Administrative Order that proposes to add a skin allergy warning to labeling requirements for acetaminophen-containing drug products.
This Proposed Safety Administrative Order addresses the GRASE status of codeine, codeine phosphate, and codeine sulfate as antitussive active ingredients.
